NC
EW icon

Nicholas Company’s Edwards Lifesciences EW Stock Holding History

Nicholas Company’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-413,220
Closed -$4.79M – 273
2013
Q3 		$4.79M Buy
+413,220
New +$4.83M 0.13% 135

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Nicholas Company's EW Position: Q4 2013 in Review

Nicholas Company sold out of Edwards Lifesciences (EW) in Q4 2013, closing a stake of 413,220 shares — an estimated $4.79M sold.

Nicholas Company first reported a position in EW in Q3 2013 and held it in 1 quarter. The position peaked at $4.79M in Q3 2013. 408 funds tracked by Wall St. Rank hold EW as of Q4 2013.

  • Nicholas Company reported no remaining Edwards Lifesciences position as of Q4 2013 after selling out during the quarter.
  • Nicholas Company sold 413,220 Edwards Lifesciences shares in Q4 2013, an estimated $4.79M.
  • Nicholas Company first reported a position in Edwards Lifesciences in Q3 2013 and held it in 1 quarter.
  • Nicholas Company's Edwards Lifesciences position peaked at $4.79M in Q3 2013.
  • 408 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2013.

Based on Nicholas Company's 13F filing for Q4 2013, filed 7 Feb 2014.